Date: 07 April 2015
We would like to congratulate researchers at The Pennine Acute Hospitals NHS Trust who have screened the first participant in the UK to a diabetes trial.
The phase 2a study’s purpose is to find out if a new investigational medication, when given together with pregabalin (Lyrica®) or gabapentin, is effective and safe in reducing pain intensity in patients suffering from neuropathic pain of diabetic origin. Pregabalin and gabapentin are approved prescription medicines that are used to treat neuropathic pain.
The new investigational product is a type of drug known as a DENKI inhibitor and works by enhancing the body’s natural pain control mechanism. The drug hasn’t been approved for the treatment of neuropathic pain of diabetic origin and is considered experimental.
Prof Bhatnagar is the study’s Principal Investigator and he’s supported by three research nurses: Joanne Shaw, Judy Muir and Louise Morby.
The Trust was able to screen a potential participant speedily due to their collaborative approach to working across their various hospital sites. Participants can be recruited from any of the Trust’s four hospitals as sub-investigators are based within each.
The first participant was found by one of the research nurses at North Manchester General Hospital, but seen at Royal Oldham Hospital as this was most convenient for the research team and the patient.
You may also be interested in